1. Company overview – what Compass Therapeutics is trying to build

Compass Therapeutics is a Boston-based clinical-stage biotech focused on antibody-based therapeutics against cancer, with a particular emphasis on bispecific antibodies that simultaneously hit angiogenesis pathways and immune checkpoints. The strategic idea is straightforward but ambitious: instead of adding another classic PD-1 inhibitor into a crowded field, CMPX aims to design molecules that re-shape the tumor vasculature and the immune micro-environment at the same time. This dual targeting is the common thread behind tovecimig, CTX-471, CTX-8371 and CTX-10726.

The company came public via reverse merger in 2020 and has since built a relatively concentrated pipeline around a few flagship assets, financed through a combination of equity raises (including a sizeable 2025 follow-on) and earlier PIPE funding. There are still no commercial products; all value is today in the probability-weighted outcome of the clinical programmes, primarily tovecimig in biliary tract cancer (BTC).

Official corporate materials and investor decks can be accessed directly on the company’s website: compasstherapeutics.com.

2. Pipeline – tovecimig is the driver, but not the whole story

2.1 Tovecimig in biliary tract cancer (BTC): pivotal data already de-risked ORR

Tovecimig (formerly CTX-009) is a DLL4 x VEGF-A bispecific antibody. DLL4 is part of the Notch pathway and plays a crucial role in tumor angiogenesis; VEGF-A is the classic VEGF ligand. By co-targeting both, tovecimig aims to generate a more profound and durable anti-angiogenic effect than VEGF blockade alone, while also modulating the tumor vasculature in a way that may improve immune cell infiltration.

The Phase 2/3 COMPANION-002 trial randomised ~168 patients with previously treated advanced BTC to receive tovecimig + paclitaxel versus paclitaxel alone. Top-line data released in April 2025 showed a statistically significant benefit on the primary endpoint objective response rate (ORR): about 17.1% ORR in the tovecimig arm (including a complete response) versus 5.3% in the control arm, with lower progressive-disease rates as well. That result effectively “de-risked” the drug on the tumour-shrinkage metric that regulators often look at first.

Importantly, Compass and its covering analysts have shifted focus to the next layer of the story: progression-free survival (PFS), overall survival (OS) and duration of response (DoR). After an initial expectation for Q4 2025, the timing for these survival analyses was pushed into late Q1 2026 because events accumulated more slowly than expected – a pattern which, in many oncology trials, is interpreted as at least compatible with meaningful clinical activity.

In parallel, an investigator-sponsored trial at MD Anderson is exploring tovecimig in first-line BTC in combination with the current standard gemcitabine/cisplatin/durvalumab regimen, with roughly 50 patients planned and 6-month PFS as a key endpoint. If the pivotal 2L trial delivers a clear survival benefit and the first-line study shows a strong signal, the drug could be positioned both as a second-line option and as an enhancer of the front-line standard of care.

2.2 Other indications and expansion potential

Beyond BTC, CMPX is preparing to move tovecimig into DLL4-positive colorectal cancer in a Phase 2 biomarker-driven setting. This is more speculative than BTC but speaks to the management’s view that DLL4-VEGF dual targeting can be relevant across a broader range of solid tumours.

2.3 CTX-471 – CD137 agonist in biomarker-selected tumours

CTX-471 is a CD137 (4-1BB) agonist antibody designed to activate T cells in the tumour micro-environment. CD137 has been a difficult target historically because of hepatotoxicity with some first-generation agents. CMPX is trying to thread the needle with a molecule that delivers sufficient immune activation while maintaining a tolerable safety profile. The company plans or has initiated Phase 2 biomarker-based trials in NCAM/CD56-expressing tumours, a relatively focused niche that may provide proof-of-concept without requiring enormous all-comers studies.

2.4 CTX-8371 – PD-1 x PD-L1 bispecific

CTX-8371 is a next-generation PD-1 x PD-L1 bispecific antibody. The novelty here is a mechanism that not only blocks the PD-1/PD-L1 axis but also induces cleavage of cell-surface PD-1, potentially overcoming some of the resistance seen with standard checkpoint inhibitors.

As of early 2026, CMPX has completed enrolment of the third dosing cohort in its Phase 1 study, with no dose-limiting toxicities reported so far and first confirmed responses in Hodgkin lymphoma and triple-negative breast cancer. These are very early signals, but they matter because they show activity beyond BTC and help justify the current pipeline premium in the stock.

2.5 CTX-10726 – PD-1 x VEGF-A, moving into the clinic

CTX-10726 is another bispecific, this time combining PD-1 blockade and VEGF-A inhibition in a single molecule. Preclinical data highlighted by CMPX suggest potent PD-1 blockade and stable bispecific structure, with the company guiding for an IND filing by late 2025 and first-in-human data in 2026.

Conceptually, CTX-10726 competes in the same broad space as combinations like pembrolizumab plus VEGF-targeting agents, but with potential dosing and mechanistic advantages. It is too early to assign meaningful value to it, yet its presence in the pipeline adds a second wave of optionality that is often appreciated by institutional investors.

3. Financial position, cash runway and potential dilution

On the financial side, Compass is still a pure cash-burn story. SEC filings and company press releases show that, as of 30 September 2025, CMPX held roughly $46M in cash and $174M in marketable securities, for a total current-asset base around $221M. In an 8-K dated 6 January 2026 the company further disclosed preliminary, unaudited cash, cash equivalents and marketable securities of about $209M as of 31 December 2025, pending final year-end closing.

Management has repeatedly guided for a cash runway into 2028, assuming current operating plans. In practice, this runway depends heavily on how quickly the company ramps up commercial-readiness spending for tovecimig and on whether it chooses to accelerate development of CTX-471, CTX-8371 and CTX-10726.

Income-statement wise, CMPX reported annual net losses in the tens of millions of dollars, driven mostly by R&D expenses for the clinical programme and G&A costs associated with scaling from a small research shop to a potential commercial-stage organisation. There is no product revenue yet, so the only real offset to cash burn comes from financing activities.

2025 also saw significant equity financing, including an upsized public offering that brought in over $100M in gross proceeds. This strengthened the balance sheet and underpins the runway guidance, but it also increased the share count and established a pattern: if CMPX remains independent and wants to fully fund multiple late-stage programmes, further dilution down the line is a realistic scenario.

4. Catalyst calendar – what really matters in 2026 and beyond

Key time window: late Q1 2026 – 2027

For traders and long-only biotech specialists alike, CMPX in 2026 is essentially a tovecimig survival-data and regulatory-pathway story, with optionality on the rest of the pipeline.

• Late Q1 2026: prespecified analyses of PFS, OS and duration of response in the Phase 2/3 COMPANION-002 BTC trial.
• 2026–2027: further maturation of BTC data (landmark survival rates, long-term safety, durability of responses).
• First-line BTC IST at MD Anderson: dose-escalation and then expansion data for tovecimig alongside gemcitabine/cisplatin/durvalumab.
• CTX-8371 updates: additional response and durability data in Hodgkin lymphoma and solid tumours as the Phase 1 continues.
• CTX-10726 first-in-human data: once the IND is cleared and patients are dosed, any early anti-tumour signal will reinforce the “platform” angle of the CMPX story.

A positive PFS/OS package in BTC, combined with clean safety and supportive first-line data, would put CMPX on a path towards potential regulatory filings and/or partnership discussions. Conversely, if survival benefits are modest or absent, the current valuation could prove difficult to sustain.

5. Trading profile – momentum, liquidity and short-squeeze optionality

Over the last year CMPX has transformed from a largely ignored micro-cap to a high-momentum small-cap biotech on the radar of both specialists and generalist growth funds. The stock has climbed close to 100% on a 12-month basis, with even stronger gains from the April 2025 pre-data lows, and recently printed 52-week highs around the mid-6-dollar area.

Liquidity has improved materially, with average daily volume in the millions of shares. That makes the name tradable for a wide range of strategies, though intraday volatility remains high.

Short-interest data show around 16.6M shares sold short, equivalent to roughly 13% of the float, and a short-interest ratio of about 7.7 days to cover. These are high enough that a clean survival readout or an unexpectedly aggressive analyst upgrade cycle could force some covering and amplify upside moves. The flip-side is obvious: if data disappoints, shorts may add rather than cover.

6. Analyst targets and institutional positioning

One of the striking features of CMPX right now is the alignment between different research houses. Across data providers, the stock carries a “Buy” to “Strong Buy” consensus, with an average 12-month target around $12–13 per share and a range that typically spans from $6–8 on the low end to $30 on the high end.

Recent notes from firms such as Raymond James, Stifel, Cantor Fitzgerald, Guggenheim, Canaccord, Citizens, LifeSci Capital and D. Boral Capital all emphasise the same core points: de-risked ORR in BTC, upcoming survival readout, robust cash position and a differentiated bispecific platform. The more aggressive targets (mid-20s to 30 $) essentially assume a best-case BTC outcome and significant probability of success in at least one second-wave asset.

From a positioning standpoint, institutional ownership sits well above 60%, with both long-only biotech funds and crossover investors represented in the shareholder base. That mix helps explain the strength of the up-move in 2025–2026, but also means that earnings calls, survival-data webcasts and ASCO/ESMO abstracts can quickly reset expectations in either direction.

7. Sentiment – what retail traders and social media are focusing on

Retail interest in CMPX has increased alongside the share-price move and the stream of pipeline headlines. Activity on social-trading platforms such as Stocktwits and on Reddit threads focused on small-cap biotech tends to spike near data releases, analyst-coverage initiations and news around survival-analysis timing. These are informal forums, populated by non-professional traders and investors, but they help to frame how the stock trades intraday.

Note: comments and sentiment on Reddit, Stocktwits and similar platforms reflect opinions of individual, non-professional users. They are not vetted, may be incomplete or biased and should never be used as a sole basis for investment decisions.

8. Risk / reward profile – how the puzzle fits together

A pragmatic way to think about CMPX is to see it as a single-asset-plus-platform story. In the bull case, tovecimig delivers strong and durable survival benefits in BTC, regulators accept ORR+survival as sufficient for approval in a population with limited options, and the first-line IST plus additional trials open the door to sizable peak-sales scenarios. In that world, the current market cap may look modest in hindsight, especially if CTX-8371 and CTX-10726 generate credible early data.

In more neutral scenarios, survival benefits are present but more modest, leading to some form of label but with tighter pricing or narrower positioning. The pipeline still has value, but the multiple compresses and the equity story becomes more balanced: upside depends on second-wave assets, and the market has to digest the impact of any further dilution.

In the bear case, survival data fail to confirm the ORR driven hype, safety or heterogeneity concerns emerge, or competitors produce clearly superior outcomes in BTC. Under those circumstances, a stock that has already re-rated above $1B can retrace sharply, and the path back to value creation becomes much longer and more uncertain.

None of these scenarios can be “predicted” with certainty. What can be said, based on publicly available data, is that CMPX is:

• Well capitalised for a clinical-stage biotech.
• Clearly high-risk, high-beta around a pivotal oncology programme.
• Backed by a fairly unified analyst community that sees more upside than downside at current prices, as long as tovecimig continues to deliver.

9. Checklist – key questions for anyone looking at CMPX

• How strong do PFS and OS need to be in BTC to justify current and higher valuation levels?
• Is management likely to pursue a partnership or attempt a largely independent commercial launch?
• How much additional capital would realistically be required under each scenario?
• What is the competitive landscape in BTC and related indications over the next 3–5 years?
• How diversified is your overall portfolio if you decide to take exposure to a name like CMPX?

These are not questions with obvious answers, but working through them is essential, especially given the combination of clinical, regulatory, market and sentiment-driven forces around the stock.

10. Educational disclaimer

This CMPX report is based exclusively on public information from SEC filings, official company press releases and major financial-news providers. Figures and timelines can change as new documents are filed or new data are released. Nothing in this text is, or should be construed as, investment advice, a stock recommendation, or a solicitation to buy or sell any security. Biotech equities are inherently risky; investors can lose part or all of their capital. Anyone considering an investment should perform their own due diligence and, where appropriate, consult a qualified financial professional.